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Wild-type HIV-1 is more infectious than nef-deleted HIV-1 in both limiting dilution and single-cycle infectivity assays.
Moreover, Nef expression from a separate plasmid in the virus-producing cells is capable of restoring the infectivity of
genetically nef-deficient HIV-1. These observations indicate that the virion itself is altered by Nef expression to promote
viral infectivity. Sucrose gradient-purified HIV-1 virions contain full-length Nef protein and its inclusion is dependent on N-
terminal myristylation of Nef. As myristylation-defective mutants of Nef do not enhance infectivity, incorporation of Nef into
virions may mediate the enhanced infectivity. Studies with recombinant Nef have further shown that HIV-1 protease can
cleave Nef into two polypeptides, a 20-kDa C-terminal core domain and a small N-terminal domain. Our analysis of purified
HIV-1 virions also showed a 20-kDa form of Nef. The generation of this 20-kDa form of Nef was inhibited by an HIV-1
protease inhibitor, and its C-terminal core domain identity was confirmed through epitope-tagging. Immunoblots of virions
demonstrated that 60–80% of the incorporated Nef is cleaved by the HIV-1 protease. This finding raised the possibility that
the Nef core domain, which may no longer be tethered to the membrane due to absence of an N-terminal myristyl anchor,
might mediate the enhanced infectivity. Therefore, a panel of mutants surrounding the proteolytic cleavage site in Nef were
analyzed for effects on cleavage and enhancement of viral infectivity. Although some Nef mutants both failed to cleave and
did not enhance viral infectivity, other mutants proved discordant in these functions. Specifically, two mutants that contained
point mutations in the N-terminal domain cleaved normally, hence generating wild-type Nef core domain, yet failed to
enhance infectivity. Thus, although the majority of the Nef protein in HIV-1 virions is cleaved by the viral protease into a
20-kDa C-terminal core domain, generation of this core domain of Nef appears insufficient to enhance HIV-1 infectivity.
These findings suggest that protease cleavage of the Nef protein in virions is irrelevant for the infectivity function of Nef.
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INTRODUCTION et al., 1989; Terwilliger et al., 1991; de Ronde et al., 1992;
Miller et al., 1994; Spina et al., 1994). We and others
The HIV-1 nef gene is located at the 3* end of the viral have shown that in single cycle infection assays, HIV-1
genome partially overlapping the U3 region of the 3* can infect 5- to 10-fold more cells than nef-deficient HIV-
LTR. Nef is a membrane-associated 27- to 29-kDa myris- 1 (Chowers et al., 1994; Miller et al., 1994). This capacity
tylated protein synthesized from early, multiply spliced alone may account for the increased replication kinetics
mRNA transcripts. The nef gene has no significant ho- of Nef/ HIV-1. The increased infectivity is manifested at
mology to other genes; however, it does contain a PxxP a stage following viral entry (Miller et al., 1995) and has
proline motif resembling a src homology type 3 (SH3) been shown to involve improved reverse transcription
binding domain (Shugars et al., 1993). Although early (Aiken and Trono, 1995; Chowers et al., 1995; Schwartz
work suggested that Nef behaved as a negative regula- et al., 1995).
tory factor, mildly suppressing both viral replication and A second well-defined function of Nef is its capacity
transcriptional activity of the HIV-1 LTR (Luciw et al., to downregulate the surface expression of CD4, a pri-
1987; Ahmad and Venkatesan, 1988; Cheng-Mayer et al., mary high-affinity receptor involved in viral entry (Guy et
1989; Niederman et al., 1989), most current in vitro data al., 1987; Garcia and Miller, 1991; Garcia et al., 1993;
demonstrate that Nef acts as a positive factor serving Mariani and Skowronski, 1993; Aiken et al., 1994). This
to augment viral replication, most notably in primary lym- function may render Nef-expressing cells less suscepti-
phocytes and macrophages (Hammes et al., 1989; Kim ble to superinfection (Benson et al., 1993). Recent studies
have shown that Nef downregulates CD4 that is already
at the cell surface and that it acts temporally before the1 To whom correspondence and reprint requests should be ad-
Vpu- and gp160-mediated effects on CD4 are observeddressed at Gladstone Institute of Virology and Immunology, Box 419100,
(Aiken et al., 1994; Rhee and Marsh, 1994; Chen et al.,San Francisco, CA 94141-9100. Fax: (415) 826-1817. E-mail:
Warner_Greene.givi@quickmail.ucsf.edu. 1996). From mutagenesis experiments, it appears that
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these two functions of Nef, the capacity to enhance viral attractive mechanism by which the myristylated and, pre-
sumably, viral membrane-associated Nef protein mightinfectivity and to reduce cell surface CD4, are indepen-
dent and appear to involve different subregions of the release a biologically active core domain of Nef. To test
whether the C-terminal core domain is sufficient to medi-molecule (Goldsmith et al., 1995; Saksela et al., 1995;
Chowers et al., 1995). Other functions of Nef are de- ate infectivity enhancement, we have generated and ana-
lyzed mutants of Nef which lack an intact protease cleav-scribed by a diverse group of studies demonstrating ef-
fects on cellular activation in T cells and thymocytes, as age site or have specific point mutations in the immedi-
ately adjacent region.well as signaling effects in nonlymphoid cells (Luria et
al., 1991; Skowronski et al., 1993; Baur et al., 1994; De
and Marsh, 1994; Graziani et al., 1996; Iafrate et al., 1997). METHODS
The relationship between these observations and CD4
Plasmid constructionsdownregulation or increased infectivity remain to be de-
fined. The proviral molecular clones used for these studies
Although there are numerous and often conflicting re- were previously described as HXB Nef/ and HXB Nef
ports with regard to the in vitro functions of Nef, the in DN-term (Miller et al., 1994). Construction of the wild-
vivo biological importance of Nef has been well estab- type Nef expression construct, pNef2 , and the myristyla-
lished in the simian immunodeficiency virus (SIV)/ma- tion mutant form of Nef, G2A, were also previously de-
caque monkey model system of AIDS where functional scribed (Goldsmith et al., 1995). To create the HA-tagged
nef is required for both high viral load and disease pro- version of Nef (Nef-HA), the nef gene was amplified from
gression (Kestler et al., 1991). More recently, a group of the proviral clone HXB Nef/ (also known as R7/3) by two
healthy HIV-1-infected people have been identified who rounds of polymerase chain reaction (PCR), each round
were infected by a single blood donor whose viral geno- adding one copy of a 12 amino acid hemagglutinin (HA)
type showed a deletion within the nef gene and the over- epitope and a glycine spacer to the 3* end of nef. The
lapping LTR (Deacon et al., 1995). Although these people amino acid sequence added to Nef would extend the
have been infected for 10–14 years, they have normal carboxy-terminus by 29 residues adding the following
CD4/ lymphocyte counts, very low viral burdens, and amino acids: GGGG YPY DVP DYA SLA G YPY DVP DYA
show no indication of HIV-1 disease. Along with other SLA. Using restriction sites within the PCR primers, the
case studies of individuals infected with nef-defective final PCR product was ligated into the pCMV4 mamma-
HIV-1 (Kirchhoff et al., 1995; Mariana et al., 1996), these lian expression vector (Anderson et al., 1989). The dele-
findings highlight the in vivo importance of the nef gene tion and point mutants of nef near the protease cleavage
product in HIV-1 pathogenesis and suggest that the nef site were created by PCR amplification of the pNef2 plas-
gene functions as a positive factor that is essential for mid utilizing two primer pairs encoding silent nucleotide
high-level viral replication in vivo. changes to introduce a unique SacII site 150 nucleotides
We have previously shown that the capacity of Nef from the start codon as well as the point or deletion
to increase viral infectivity can be reconstituted by Nef mutation. The two fragments were joined at the SacII site
expression in trans in cells producing genetically nef- and the 150-bp portion of the nef gene between the XhoI
deficient HIV-1 (Miller et al., 1995). These observations and the BglII restriction sites (nucleotides 102–256) was
indicate that the virions produced by Nef-expressing subsequently subcloned into the Nef-HA plasmid. The
cells are intrinsically altered. We were unable to define predicted nucleotide sequences of all constructs were
changes in either the envelope or Gag proteins in our rigorously confirmed by automated DNA sequencing.
earlier studies. In the current work, we observe that the
myristylated Nef protein itself is incorporated into HIV-1 Virus production
virions. Previous investigations using recombinant Nef
and recombinant HIV-1 protease have shown that Nef Virus was produced by transfection of 293T cells (Pear
et al., 1993) with proviral HIV-1 DNA alone or togethercould be cleaved between residues 57 and 58 generating
two Nef polypeptides (Freund et al., 1994; Gaedigk- with Nef wild-type or Nef mutant expression vectors by
the calcium phosphate method as previously describedNitschko et al., 1995). We present evidence that the HIV-
1 protease also mediates cleavage of Nef in sucrose (Goldsmith et al., 1995; Miller et al., 1995). In nef cotrans-
fection experiments, the DNA was precipitated in a molargradient-purified virions. As we and others have shown
that Nef’s effect on HIV-1 infectivity is mediated at a plasmid ratio of 1:4 of the nef-deleted proviral DNA to
nef-expression vector. For experiments with the HIV-1postentry stage in the newly infected target cell (Aiken
and Trono, 1995; Chowers et al., 1995; Miller et al., 1995; protease inhibitor A77003 (Kempf et al., 1991) (a gener-
ous gift of Dale Kempf, Abbott Laboratories), the transfec-Schwartz et al., 1995), we hypothesized that Nef in the
virion might directly or indirectly mediate these postentry tions were carried out in the presence of the indicated
concentrations of the inhibitor. The inhibitor was firsteffects on infectivity. Furthermore, cleavage of virion-as-
sociated Nef by the HIV-1 protease would provide an diluted to 1 mM in DMSO prior to dilution in media. For
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some studies, H9 cells were infected with transfection AIDS Reference and Reagent Program, diluted 1:3000),
or an anti-HA monoclonal antibody (12CA5, Boeringerproduced virus and cultured for 7–10 days. The peak
of virus replication was determined by Gag p24 ELISA Mannheim, Indianapolis, IN; diluted 1:3000). Blots were
subsequently incubated with horseradish peroxidase-(DuPont Medical Products, Boston, MA) and the virus
stored at 0707. conjugated donkey anti-rabbit Ig (Amersham, Arlington
Heights, IL), donkey anti-mouse Ig (Amersham), or goat
Virus purification anti-sheep Ig (Zymed, So. San Francisco, CA), all diluted
1:3000 in PBS containing 0.5% Tween 20. Immunoreac-
For sucrose gradient purification of virus, 30 ml of clari-
tive bands were visualized using the ECL Detection Sys-
fied viral supernatant was filtered through a 0.45-mm filter
tem according to the manufacturer’s instructions (Amer-
and then layered over 7 ml of 20% sucrose in PBS in
sham).
45-ml centrifuge bottles. Virus was pelleted through the
sucrose using a JS13.1 swinging bucket rotor at 26,500 Single-cycle HIV-1 infectivity assay
g for 5 hr in a Beckman J2-MC high-speed centrifuge. The
supernatant followed by the sucrose layer was carefully We have developed an assay to measure directly viral
gene expression in infected cells using an anti-Gag p24aspirated. The viral pellet was taken up in 500 ml of PBS
containing 2% fetal bovine serum and the concentration monoclonal antibody and detergent permeabilization of
the cells. Specifically, a HeLa-CD4 cell line (Kimpton andof Gag p24 determined by ELISA. Continuous sucrose
gradients were prepared by sequentially underlaying 2.5 Emerman, 1992) was infected with dilutions (2:3, 1:3, and
1:6) of viral transfection supernatants in 24-well plates.ml of 15, 25, 35, and then 45% sucrose (w/v in PBS) and
then allowing passive diffusion for 24 hr. Two micro- The next day, soluble CD4 was added to a concentration
of 10 mg/ml to prevent new cycles of infection. Forty hrgrams of pelleted Gag p24 was added to the preformed
sucrose gradients and the 12-ml tubes were transferred later, the cells were lifted from plates with trypsin and
transferred to V bottom 96-well plates. The cells wereto a Beckman SW41.Ti Rotor. The samples were centri-
fuged at 200,000 g for 18 hr at 47. Fourteen 750-ml frac- fixed and permeabilized using the Fix and Perm kit (Cal-
tag, So. San Francisco, CA) in 25-ml volumes. Includedtions were collected from the bottom of the tube and
analyzed for percentage of sucrose using a refractome- in the permeabilization solution was an anti-Gag p24
monoclonal antibody (KC57, Coulter, Hialeah, FL) at ater. One PBS volume was added to each fraction and the
samples were pelleted in a microcentrifuge for 90 min 1:1600 final dilution. The cells were washed, stained with
FITC-conjugated goat anti-mouse Ig (Becton–Dickinson,at 14,000 g. All volume was aspirated and the samples
were solubilized in SDS/PAGE loading buffer. When gra- Mountain View, CA), washed again, and then analyzed
by flow cytometry for fluorescence. Gag p24-expressingdient purification was not performed, clarified viral super-
natants corresponding to 250 ng of Gag p24 were directly cells appeared as a distinct peak with a median fluores-
cence greater than one log above that of uninfected cells.pelleted in the microcentrifuge and then lysed in SDS/
PAGE loading buffer. Infection of cells pretreated with AZT did not demonstrate
a second peak of Gag p24-positive cells, indicating that
Immunoblots the input Gag p24 from the viral particles was not signifi-
cant in this analysis (data not shown). The percentage
Viral lysates were boiled for 15 min in SDS/PAGE load-
of Gag p24-positive cells for each dilution of virus was
ing buffer. Cell lysates were prepared by removing the
plotted against the actual Gag p24 concentration of the
transfected 293T cells with TEN (40 mM Tris–Cl, pH 7.5,
input virus as determined by ELISA. An interpolated value
1 mM EDTA, pH 8.0, 150 mM NaCl), pelleting the cells
of the percentage of infected cells at 25 ng/ml of input
and then directly lysing them in SDS/PAGE loading
virus was determined.
buffer. To fully solubilize the cells, the samples were
boiled for 1 hr prior to loading. Portions of the viral or CD4 downregulation
cellular lysates were loaded on 13% polyacrylamide gels
and electrophoresed. SeeBlue (Novell, San Diego, CA) COS7 cells (from the American Type Culture Collec-
tion) were passaged in Iscove’s medium (Cellgro: Medi-prestained molecular weight standards (4–250 kDa)
were included in each gel. The proteins in the gels were atech, Washington, DC) supplemented with 10% FCS and
antibiotics (complete Iscove’s). Approximately 20 hr be-transferred onto nitrocellulose membranes (Schleicher
and Schuell, Keene, NH). The blots were blocked in 5% fore transfection, 3.5 1 105 cells were plated in duplicate
into each well of a 6-well plate in 2.0 ml of Iscove’snonfat dry milk and 0.5% Tween 20 in PBS for 1 hr and
then incubated with primary antibodies diluted in fresh medium. Cells were transfected using Lipofectamine
(GIBCO-BRL) with a human CD4 expression plasmidblocking solution, either a sheep polyclonal anti-Gag p24
or anti-Gag p17 antisera (Cat. Nos. 287 and 288, AIDS (pCD4neo) alone or in combination with expression vec-
tors encoding wild-type or mutant versions of Nef at anReference and Reagent Program, each diluted 1:2000),
a rabbit polyclonal anti-NefBH10 antisera (Cat. No. 2121, input ratio of 1:6 (Goldsmith et al., 1995). DNA concentra-
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tion was held constant for all transfections. After 30–
35 hr of culture, the cells were harvested, stained with
Phycoerythrin-conjugated anti-CD4 monoclonal antibod-
ies (Becton–Dickinson, San Jose, CA), and analyzed on a
FACScan (Becton–Dickinson). Stable expression of wild-
type Nef and the various Nef mutants was confirmed by
immunoblotting of the cell lysates with either anti-Nef or
ant-HA epitope antibodies.
RESULTS
Myristylated Nef protein associates with HIV-1 virions
purified by sucrose density gradients
Our previous work had shown that the production of
HIV-1 from cells expressing Nef in trans resulted in viral
particles with intrinsically augmented infectivity, indicat-
ing that the virion itself is altered (Miller et al., 1995).
As alterations in the major structural proteins were not
detected, we questioned whether the Nef protein itself
might be incorporated into viral particles. HIV-1 was pro-
duced in an acutely infected H9 cell line, concentrated,
and then purified by sucrose density gradient centrifuga-
FIG. 1. The myristylated Nef protein associates with sucrose gradienttion. Sequential fractions were collected and analyzed
purified HIV-1 virions. (A) Concentrated wild-type HIV-1 generated fromfor both sucrose density and Gag p24 concentration.
an acute infection of H9 cells was purified by buoyant density centrifu-Fraction 9 contained the peak concentration of Gag p24
gation through continuous sucrose gradients. Fractions 3–14 were
by ELISA and corresponded to a sucrose density of ap- pelleted by microcentrifugation and electrophoresed by SDS/PAGE.
proximately 1.16 g/ml, consistent with the buoyant den- Immunoblots were prepared using a cocktail of a sheep polyclonal
antiserum to Gag p24 and a rabbit polyclonal Nef antiserum to Nef.sity of intact HIV-1 particles. The fractions were also
The positions of Nef and Gag p24 are indicated. Levels of both proteinsanalyzed by SDS/PAGE and immunoblots using a cock-
peak within fraction 9, which by refractometry corresponds to a densitytail of anti-Gag p24 and anti-Nef immune sera (Fig. 1A).
of 1.16 g/ml. Lane 2 contains one-tenth of the crude concentrated HIV-
The results demonstrate that both Nef and Gag p24 co- 1 used for the gradient. Lane 1 contains a similar quantity of Nef0 HIV
purify in the same fractions and indicate that Nef associ- (HXB Nef DN-term) also produced from acutely infected H9 cells. (B)
HIV-1 was produced by cotransfection of 293T cells with Nef0 HIV andates with HIV-1 virions. Purification of HIV-1 produced by
the myristylation deficient form of Nef, G2A (Goldsmith et al., 1995).transiently transfecting nef-defective HIV-1 along with a
The HIV-1 was purified and analyzed as described above. (C) TheNef-expression plasmid in trans yielded identical immu-
myristylation deficient form of Nef is expressed in the cells producing
noblot results (data not shown). However, a myristylation virus. Cell lysates from 293T cells cotransfected with Nef0 HIV and Nef
mutant form of Nef, containing a glycine to alanine substi- G2A (lane 4), Nef0 HIV and pNef2 (lane 3), Nef0 HIV alone (lane 2), or
wild-type Nef/ HIV-1 (lane 1) were analyzed by immunoblotting withtution at position 2 (G2A), does not associate with HIV-
the anti-Nef antisera.1 virions by this method (Fig. 1B). Although small quanti-
ties of Nef G2A can be detected in crudely pelleted virion
preparations (lane 2 of Fig. 1B), this Nef does not enter
Lower molecular weight forms of Nef also associate
sucrose gradients and does not copurify with HIV-1 viri-
with HIV-1 virions
ons. Figure 1C verifies the expression of the myristyla-
tion-deficient form of Nef in the cells producing the HIV- Several studies in cell-free systems have shown that
Nef can be cleaved by recombinant HIV-1 protease into1. Thus, the association of Nef with HIV-1 virions appears
dependent on its capacity to be modified by the addition two polypeptides, an amino-terminal anchor domain and
a carboxy-terminal domain, the latter termed the coreof an N-terminal myristyl group and its subsequent asso-
ciation with cellular membranes. As we have previously domain of Nef (Fig. 2A) (Freund et al., 1994; Gaedigk-
Nitschko et al., 1995). These polypeptides were shownshown that the G2A myristylation mutant of Nef does not
enhance viral infectivity (Goldsmith et al., 1995; also see to migrate at approximately 9- and 20-kDa, respectively,
as observed by SDS–PAGE. Peptide sequence analysisFig. 6), the association of myristylated Nef with virions
correlates with enhanced infectivity. The identification of defined the cleavage site to lie between the tryptophan
and leucine residues at positions 57 and 58. Figure 2BNef in virions has also been recently described by three
other laboratories (Pandori et al., 1996; Welker et al., shows an anti-Nef immunoblot of gradient-purified HIV-
1 virions. In addition to the full-length Nef band at 291996; Bukovsky et al., 1997).
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kDa, there is notable anti-Nef immunoreactive protein
migrating at 20 kDa and a diffuse band or bands migrat-
ing ahead of that. From these observations, we hypothe-
sized that the 20-kDa species of Nef represents the car-
boxy-terminal core domain of Nef and the more diffuse
band(s) represent the N-terminal domain.
Appearance of the 20-kDa core domain of Nef can be
inhibited by HIV-1 protease inhibitors
In order to confirm that the HIV-1 protease is involved
in the generation of the lower molecular weight Nef spe-
cies, we produced virions by transfection of the HIV-1
molecular clone HXB Nef/ in the presence of increasing
doses of an HIV-1 protease-specific inhibitor A77003
(Kempf et al., 1991). Equivalent quantities of transfection
supernatants were pelleted and viral lysates were then
subjected to SDS/PAGE and immunoblotting with anti-
Nef or a cocktail of anti-Gag p17 and p24 antisera. The
20-kDa form of Nef diminished with increasing doses of
the inhibitor and was undetectable at an inhibitor con-
centration of 2 mM (Fig. 3A), implicating the HIV-1 prote-
ase in the formation of this form of Nef. Moreover, the
full-length form of Nef increased in abundance in the
presence of the drug, suggesting a precursor–product
relationship between these forms. Similar concentrations
FIG. 3. The generation of the lower molecular weight forms of Nefof the HIV-1 protease inhibitor were effective at inhibiting
and the cleavage of Gag p55 into p24 and p17 are inhibited by an HIV-
1 protease inhibitor. (A) Nef/ HIV was produced by transfection of 293T
cells in concentrations of the HIV-1 protease inhibitor A77003 ranging
from 0 to 8 mM. Pelleted virions from 1 ml of viral supernatant were
electrophoresed and immunoblotted with the anti-Nef antiserum. The
positions of the full-length Nef and C-terminal cleavage product are
indicated along with the molecular weight standards. Lane 1 contains
HIV-1 produced by transfection with the nef-defective proviral construct
HXB Nef DN-term. (B) Immunoblot of the samples described above
using the sheep polyclonal antiserum to both Gag p24 and Gag p17.
To demonstrate Gag specificity, lane one contains pelleted supernatant
from untransfected 293T cells. (C) Cell lysates from the transfected
293T cells demonstrate expression of full-length Nef under all inhibitor
conditions. An immunoblot was prepared from the transfected cell ly-
sates using the anti-Nef antiserum.
the cleavage of the Gag p55 precursor into the p17 and
p24 cleavage products (Fig. 3B). The cells which pro-
duced the virus were also lysed, electrophoresed, and
immunoblotted for Nef (Fig. 3C). Nef expression in cells
was consistent at all doses of the protease inhibitor.
Moreover, there was no evidence of the 20-kDa Nef core
domain in the cellular lysates, consistent with HIV-1 pro-
FIG. 2. (A) Schematic of the proteolytic cleavage of Nef by the HIV- tease activity occurring predominantly within the budding
1 protease into a 9-kDa N-terminal membrane anchor domain and a virion (Kaplan et al., 1994). These observations indicate
20-kDa C-terminal core domain as defined in cell-free systems using
that the 20-kDa form of Nef observed in HIV-1 virions isrecombinant proteins (Freund et al., 1994; Gaedigk-Nitschko et al.,
a cleavage product of full-length Nef that is generated1995). (B) Lower molecular weight forms of Nef also associate with
purified HIV-1 virions. Wild-type HIV-1 was prepared from an acutely by the HIV-1 protease during virus maturation.
infected H9 cell line and fractionated as described in the legend of
Fig. 1. This immunoblot was prepared with freshly diluted anti-Nef Carboxy-terminal epitope tagging of Nef
antisera. Lanes 1 and 2 contain crude pelleted HIV-1 prepared from
To determine whether the 20-kDa Nef cleavage prod-Nef0 or Nef/ HIV-1, respectively. The values (in kDa) of the molecular
weight markers (Rainbow, 14.3 – 220 kDa; Amersham) are indicated. uct includes the carboxy terminus of the protein, we uti-
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lized a Nef expression vector, Nef-HA, which contains
the entire nef coding sequence followed at its 3* end by
two copies of an influenza hemagglutinin (HA) epitope.
HIV-1 was produced by cotransfection of a nef-defective
HIV-1 proviral construct along with the Nef-HA vector.
Concentrated viral lysates were immunoblotted with ei-
ther anti-Nef polyclonal sera or an anti-HA monoclonal
antibody (Fig. 4A). The anti-Nef immunoblot of Nef/ HIV-
1 shows the two expected bands corresponding to the
FIG. 5. Protease cleavage analysis of mutants of Nef near the primaryfull-length and the 20-kDa protease-cleaved forms of Nef.
cleavage site. HA-tagged cleavage site mutants of Nef, diagrammed
The Nef-HA HIV lane also shows two major Nef-specific in Fig. 8, or Nef-HA were cotransfected with nef-defective HIV-1 in 293T
bands, both migrating slightly slower than their corre- cells. The quantity of virus corresponding to 250 ng of Gag p24 was
pelleted by microcentrifugation. The proteins in the viral lysate weresponding nontagged forms of Nef due to the addition of
separated by SDS/PAGE and immunoblotted with the anti-HA mono-the 29 amino acid epitope tag. On the right side of Fig.
clonal antibody. The primary core cleavage product was not detectable4A, the anti-HA immunoblot detected both of the major
in virions prepared with the WL57GG or the D55–57 Nef mutants.
Nef-specific bands seen in the Nef-HA HIV lane of the
anti-Nef immunoblot, indicating that these two forms of
Nef contain the C-terminal epitope tag. Interestingly, a ized in the anti-HA immunoblot but was barely detectable
third band, migrating around 18 kDa, was readily visual- in the anti-Nef immunoblot. As neither of these C-terminal
forms of Nef are present when the Nef-HA HIV-1 virions
are produced in the presence of the HIV-1 protease inhib-
itor (data not shown) and as they are both detectable in
sucrose gradient purified virions (Fig. 4B), these observa-
tions suggest the possibility of a second HIV-1 protease
cleavage site within Nef. The use of HA-tagged Nef also
permits a more reliable estimation of the proportion of
Nef in either the full-length or cleaved forms as the immu-
noreactivity of the carboxy HA epitope would be unaf-
fected by cleavage events. From immunoblots of gradient
purified virus and densitometry analysis of the film using
a Stratagene Eagle Eye video camera, we estimate that
typically 60–80% of Nef in the virion is in a cleaved form
depending on the particular viral prep (Fig. 4B).
Mutagenesis of the major protease cleavage site in nef
Previous analysis of Nef cleavage by the HIV-1 prote-
ase had demonstrated a cleavage site between residues
57 and 58 (Freund et al., 1994; Gaedigk-Nitschko et al.,
1995). We therefore created a panel of mutants in thisFIG. 4. (A) C-terminal epitope tagging of Nef demonstrates the C-
terminal identity of the major cleaved form of Nef and reveals a second- region of nef attempting to interfere with HIV-1 protease
ary cleavage product. HIV-1 was produced by transfection of 293T cells activity at this site either through small deletions or spe-
with either Nef0 HIV or Nef/ HIV or by cotransfection of Nef0 HIV cific point mutations (see Fig. 8). All of these Nef mutants
with the Nef-expression plasmid Nef-HA. Pelleted viral lysates were
were created in the Nef-HA vector to facilitate the analy-separated by SDS–PAGE, loading either 50 or 500 mg of Gag p24.
sis of expression and cleavage. HIV-1 was produced byProteins were transferred onto a single nitrocellulose membrane and
the membrane was cut in half. One half was developed with anti-Nef cotransfection of 293T cells with the indicated Nef mutant
antisera (500-mg samples) and the other with the anti-HA monoclonal or wild-type Nef along with nef-defective HIV-1. Anti-HA
antibody (50-mg samples). The nitrocellulose membrane was reassem- immunoblots of viral lysates from pelleted virions demon-
bled before development with ECL to compare directly migration be-
strated the expected full-length and core forms of Neftween the lanes. In this immunoblot, an additional nonspecific band is
when nef-defective HIV-1 was cotransfected with HA-seen in all lanes migrating between the tagged and nontagged full-
length forms of Nef. (B) Both the primary and secondary cleavage tagged Nef (Fig. 5). Four of the Nef cleavage site mutants
products of Nef associate with gradient-purified HIV-1. The Nef-HA (W57A, CAW55LLL, WL57AA, and E59A) continued to be
HIV-1 described above was purified by buoyant density centrifugation recognized by the HIV-1 protease as demonstrated by
as described in the legend of Fig. 1. In this gradient, fraction 8 corre-
the presence of the core cleavage product in virions. Insponded to the peak Gag p24 concentration as determined by ELISA.
contrast, two other mutants, WL57GG and D57–59,Fractions 3– 14 were separated by SDS/PAGE and an immunoblot pre-
pared with the anti-HA monoclonal antibody. failed to yield any detectable core cleavage product.
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None of these mutations impaired incorporation of the
full-length Nef protein into virions.
Expression of a wild-type core domain of Nef is
insufficient to enhance viral infectivity
We have developed a single cycle infectivity assay to
monitor directly viral gene expression rather than the
trans activation of a reporter gene. Specifically, CD4/
HeLa cells are infected with various quantities of HIV-1,
further rounds of infection are blocked by the addition of
sCD4 at 18 hr, and then the cells are permeabilized with
detergent after 40 hr. Infected cells are immunostained
for cytoplasmic Gag p24 and directly quantitated by flow
cytometry. This direct viral gene expression analysis typi-
cally demonstrates that Nef/ HIV-1 can infect approxi-
FIG. 7. CD4 down-regulation by the various Nef mutations occurringmately 5- to 10-fold more cells than an identical quantity
at or near to the primary HIV-1 protease cleavage site. COS7 cellsof nef-defective HIV-1 produced from transfected 293T were transfected with pCD4neo and Nef expression vectors as de-
cells. In this assay, both the wild-type Nef and the HA- scribed under Methods. Cells were stained with phycoerythrine conju-
tagged Nef can function in trans to rescue fully the infec- gated anti-CD4 antibody and analyzed by flow cytometry. The assay
was performed in duplicate and each sample stained and analyzedtivity of nef-defective HIV-1 (Fig. 6). As previously de-
independently. Of all of the mutants examined, only Nef E59A displayedscribed, the myristylation mutant form of Nef, G2A, fails
wild-type CD4 down-regulating activity.to restore infectivity (Goldsmith et al., 1995). In the current
mutant panel, expression of all but one of the Nef cleav-
age site mutants failed to rescue the infectivity. The sin- failed to rescue infectivity (D55–57 and WL57GG), three
gle functional mutant, Nef E59A, changes a strictly con- other mutants, W57A, WL57AA, and CAW55LLL, all of
served glutamic acid residue at position 59 (Meyers et which maintained wild-type cleavage by the viral prote-
al., 1995) to alanine and was also readily cleaved by the ase, failed to rescue infectivity. These results are summa-
HIV-1 protease (see Fig. 5). Although the two mutants rized in Fig. 8. Importantly, as the W57A and CAW55LLL
which failed to be cleaved by the viral protease also mutants are only altered in their N-terminal domain, their
successful cleavage by the viral protease yields a C-
terminal Nef core domain that is wild type in sequence.
Thus, these results indicate that generation of a wild-
type C-terminal Nef core domain by the viral protease
in virions is insufficient to mediate the enhancement of
infectivity by Nef.
Studies were also performed to assess the ability of
these various Nef mutants to downregulate cell surface
CD4 (Fig. 7). We found that all of the Nef mutants except
E59A also lacked the ability to down-regulate CD4.
DISCUSSION
In the present work, we demonstrate that the Nef pro-
tein itself is incorporated into sucrose gradient-purified
HIV-1 virions, regardless of whether Nef is expressed in
cis or in trans, and we provide evidence that myristylation
is necessary for such incorporation. In cell-free systems,
recombinant HIV-1 protease can cleave recombinant NefFIG. 6. Infectivity analysis of HIV-1 prepared with mutants of Nef
between residues W57 and L58 (Freund et al., 1994; Gae-near the primary cleavage site. The virus prepared and analyzed in
Fig. 5 was also evaluated for its infectivity. MAGI cells (Kimpton and digk-Nitschko et al., 1995). As has been shown for recom-
Emerman, 1992) were infected with standard dilutions of viral super- binant Nef, we observed that the Nef included in the
natant as described under Methods. The percentage of infected cells virion was cleaved by the HIV-1 protease generating a
was determined by flow cytometry of detergent permeabilized cells
C-terminal core domain of Nef. This work confirms recentstained with an anti-p24 monoclonal antibody. A linear regression
publications which also demonstrate a protease-cleavedanalysis was performed for each virus stock to determine by interpola-
tion the percentage of infected cells at 25 ng/ml of Gag p24. form of Nef in pelleted or exclusion chromatography-
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FIG. 8. Diagrammatic representation and functional summary of the panel of Nef cleavage site mutants. Amino acid residues 52–61 of the wild-
type Nef are indicated with single letter notation in the first line. The amino acid sequence of the mutants of Nef are shown with indicated amino
acid substitutions (single letter code), with indicated deletions (. . .) or as wild-type sequence (0). Under the cleavage column, ‘‘Yes’’ denotes
detectable generation of core cleavage product in Fig. 5. Under the infectivity column, ‘‘Yes’’ denotes successful rescue of infectivity as shown in
Fig. 6. Under the CD4 Down-regulation column, ‘‘Yes’’ denotes successful downregulation of cell surface CD4.
purified Nef/ HIV-1 preparations (Pandori et al., 1996; this N-terminal fragment was observed in the studies
using recombinant Nef and HIV-1 protease in cell-freeWelker et al., 1996; Bukovsky et al., 1997). We created a
panel of mutants to characterize the site of the cleavage cleavage reactions (Freund et al., 1994; Gaedigk-
Nitschko et al., 1995), we conclude that either degrada-of Nef in virions and to assess whether Nef cleavage is
involved in its enhancement of viral infectivity. We found tion occurs within virions or that the myristylated tail
dramatically affects the migration of the membrane an-this a particularly attractive hypothesis as it provided a
mechanism by which the viral membrane-associated Nef chor domain in SDS/PAGE. The possibility that the HIV-
1 protease would mediate this degradation is unlikelyprotein could be released from its membrane anchor
potentially to interact directly with the viral core or viral since this did not appear to occur in the cell-free systems.
The use of the C-terminal epitope-tagged form of Nefpreintegration complex.
Our studies indicated that introduction of a single point permits a more precise definition of what proportion of
the incorporated Nef is cleaved by the HIV-1 proteasemutation at tryptophan 57, W57A, or the triple mutation
CAW55LLL did not impair cleavage. In fact, the as antibody recognition of the HA epitope is unaffected
by cleavage. Using the anti-HA antibody, we routinelyCAW55LLL mutant consistently demonstrated even
greater cleavage than wild-type Nef. However, these two observe between 60 and 80% of incorporated Nef in a
cleaved form. Interestingly, using the HA epitope tag ver-Nef mutants failed to rescue infectivity of nef defective
HIV. When coupled with the fact that cleavage of both of sion of Nef, we have also often observed another smaller
form of a carboxy-terminal Nef polypeptide, indicatingthese mutants generated wild-type core domains (Fig. 8)
we conclude that generation of the cleaved C-terminal the possibility of a second downstream protease cleav-
age site (see Fig. 4). Of note, a second proteolytic cleav-Nef core domain is insufficient to mediate infectivity en-
hancement, refuting our original hypothesis. Moreover, age site in HIV-1 Nef, between residues G98 and L99,
has recently been reported in cell-free systems usingthe N-terminal domain would also be insufficient to aug-
ment infectivity as it does not contain the PxxP motif recombinant HIV-2 protease (Schorr et al., 1996). How-
ever, since abrogation of the 57/58 site results in a com-previously shown to be important for the enhancement
of infectivity (Goldsmith et al., 1995; Saksela et al., 1995). plete loss of infectivity function for some Nef mutants
(e.g., WL57GG and WL57AA), but does not affect the for-Together, these data suggest that protease cleavage of
Nef in HIV-1 particles is likely irrelevant to the infectivity mation of this smaller product (data not shown), we con-
clude that the generation of this smaller core product isfunction of Nef.
Although the C-terminal core domain of Nef was also insufficient for the rescue of infectivity enhancement.
We created the E59A Nef mutant expecting that thisreadily apparent in immunoblots of virions, the N-terminal
membrane anchor domain was difficult to detect and analogue would not be a suitable substrate for the HIV-
1 protease since a glutamic acid at the P2* position rep-appeared only as a very diffuse band (Fig. 2B). A commer-
cial monoclonal antibody against the N-terminal region resents a fairly well-conserved residue among known
viral and nonviral HIV-1 protease substrates (Tomasselliof Nef (NEA9302, DuPont) did confirm the N-terminal
identity of this diffuse band but did not develop the band and Heinrikson, 1994). To our surprise, this mutant form
of Nef was readily cleaved by the HIV-1 protease. Thesewith any greater signal strength (data not shown). Since
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findings extend the existing observations indicating the tion (Chowers et al., 1994; Aiken and Trono, 1995; Gold-
smith et al., 1995). As Nef expression during the produc-flexibility of HIV-1 protease substrate recognition. Indeed,
we also found that the WL57AA mutant of Nef which tion of virus is sufficient to enhance viral infectivity, there
may be other alterations in the viral particle, in additionlacks both of the normal amino acids at the cleavage
site was effectively cleaved. It appears that regulation of to the small quantities of Nef, which are responsible
for increasing particle infectivity. The demonstration thatHIV-1 protease activity is not through precisely defined
amino acids sequences in a substrate, but, rather, the several cellular kinases can associate with Nef provides
a potential mechanism to affect these virion alterationsprotease is only active upon the dimerization of the Gag/
Pol precursor which occurs in the budding virion (Kaplan (Sawai et al., 1994; Saksela et al., 1995; Nunn and Marsh,
1996; Baur et al., 1997). As Nef is a critical factor for HIV-et al., 1994; Tomasselli and Heinrikson, 1994). This rele-
gation of HIV-1 protease activity to budding virions would 1 pathogenesis and disease progression, elucidation of
the molecular basis for its capacity to increase viral infec-protect cellular proteins from HIV-1 protease activity. In
support of this, we do not detect significant levels of tivity may provide insights into therapeutic options that
target Nef function in vivo.cleaved Nef in lysates of cells producing HIV-1 (Fig. 2C).
Interestingly, investigations targeting nonviral reporter
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